{
    "nct_id": "NCT04892472",
    "official_title": "EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of stage III or metastatic NSCLC without EGFR sensitizing mutation or ALK translocation\n* Age ≥ 22 years\n* Have a PD-L1 positive (TPS≥1%) tumor by local laboratory assessment\n* Have evaluable (measureable or non-measureable) disease in thorax per RECIST 1.1\n* ECOG performance status of 0 to 1\n* Have not received prior treatments for metastatic or current advanced NSCLC. Palliative treatment is allowed and subjects who received adjuvant, neoadjuvant chemotherapy or chemoradiotherapy with curative intent for non-metastatic disease are eligible if therapy completed at least 12 months prior to the development of metastatic or current advanced disease.\n* Life expectancy of at least 3 months\n* Able to operate the NovoTTF-200T device\nHealthy volunteers allowed\nMust have minimum age of 22 Years",
    "exclusion_criteria": "* Has known active or untreated CNS metastases and/or carcinomatous meningitis\n* Has an EGFR sensitizing mutation and/ or ALK translocation\n* Can be treated with curative intent with either surgical resection and/or chemoradiation\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or co-inhibitory T cell receptor within the past 12 months\n* Has received prior systemic anti-cancer therapy for metastatic or current advanced NSCLC (palliative radiotherapy is allowed)\n* Being unable to operate the NovoTTF-200T device independently or with the help of a caregiver\n* Pregnancy or breastfeeding\n* Received live vaccine in the past 30 days or had major surgery in the last 3 weeks\n* Is expected to require any other form of systemic or localized antineoplastic therapy while on study",
    "miscellaneous_criteria": ""
}